Adaptive Biotechnologies Corp
$ 16.90
-6.53%
05 Jun - close price
- Market Cap 2,675,942,000 USD
- Current Price $ 16.90
- High / Low $ 18.29 / 16.68
- Stock P/E N/A
- Book Value 1.36
- EPS -0.32
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.24 %
- 52 Week High 20.76
- 52 Week Low 9.90
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$20.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-05 | 2025-11-05 | 2025-08-05 | 2025-05-01 | 2025-02-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-02-14 | 2023-11-09 | 2023-08-02 |
| Reported EPS | -0.13 | -0.09 | 0.06 | -0.17 | -0.2 | -0.23 | -0.22 | -0.29 | -0.32 | -0.3 | -0.35 | -0.33 |
| Estimated EPS | -0.16 | -0.18 | -0.14 | -0.24 | -0.31 | -0.24 | -0.27 | -0.33 | -0.34 | -0.33 | -0.34 | -0.35 |
| Surprise | 0.03 | 0.09 | 0.2 | 0.07 | 0.11 | 0.01 | 0.05 | 0.04 | 0.02 | 0.03 | -0.01 | 0.02 |
| Surprise Percentage | 18.75% | 50% | 142.8571% | 29.1667% | 35.4839% | 4.1667% | 18.5185% | 12.1212% | 5.8824% | 9.0909% | -2.9412% | 5.7143% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADPT
2026-06-04 20:34:13
Adaptive Biotechnologies Corp (ADPT) filed a Form 144, indicating proposed sales of equity derived from prior awards. The filing details 10,000 shares from exercised stock options and 1,000 restricted stock units. It also reports the sale of 41,338 shares during the past three months for over $544,000, with Morgan Stanley Smith Barney LLC identified as the broker-dealer.
2026-06-04 20:28:13
An affiliate of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has filed a Form 144 to notify a planned sale of common stock. The filing details proposed sales linked to an option exercise of 21,865 shares on June 4, 2026, and 20,220 shares from restricted stock units dated March 4, 2025. It also reports prior Rule 10b5-1 sales totaling 91,231 shares between March and April 2026, with associated proceeds.
2026-06-04 09:39:06
Adaptive Biotechnologies (NASDAQ:ADPT) is focusing on expanding its minimal residual disease (MRD) testing business with clonoSEQ, which has achieved profitability and positive cash flow for its MRD segment in 2025. The company also aims for targeted partnerships for its Immune Medicine platform, with a goal of achieving positive adjusted EBITDA and free cash flow for the entire company by the end of 2026. CEO Chad Robins highlighted clonoSEQ's strong adoption, expanding coverage, and increasing use in pharmaceutical trials, while noting the Immune Medicine platform's focus on data monetization and strategic collaborations.
2026-06-03 18:00:00
Adaptive Biotechnologies Corporation reported a 35% year-over-year revenue increase in Q1 2026, reaching $70.9 million, primarily driven by its Minimal Residual Disease (MRD) business and clonoSEQ product. The company also reduced its net loss and narrowed its non-GAAP Adjusted EBITDA loss. Consequently, Adaptive Biotechnologies raised its full-year 2026 MRD revenue guidance to $260 million to $270 million, highlighting its strong financial position and market leadership in immune medicine.
2026-06-03 14:00:00
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) reported strong Q1 2026 results, with total revenue increasing 35% year-over-year to $70.9 million, primarily driven by its Minimal Residual Disease/MRD business. The company's clonoSEQ product saw a 41% rise in test volume, contributing to a reduced net loss and narrowed non-GAAP Adjusted EBITDA loss. Adaptive Biotech also raised its full-year 2026 MRD revenue guidance to $260-$270 million, supported by healthy cash reserves and a focus on growth in clinical testing and drug development.
2026-06-01 12:40:37
Adaptive Biotechnologies' clonoSEQ test for measurable residual disease was prominently featured at major oncology conferences (ASCO and EHA) with 33 presentations, reinforcing its position as a key tool in hematologic oncology. While this strengthens the near-term revenue outlook for the company's MRD segment, investors should still consider the ongoing company-wide losses and potential future funding needs as a significant risk. The increased visibility supports previous optimistic analyst forecasts but does not fundamentally alter the investment narrative regarding long-term profitability.
